Quick Summary:
In the dynamic and evolving world of mental health treatments, the global psychedelic drugs market stands out as an area of significant interest. Alternative treatment modalities for mental health disorders graduate from experimental research studies to mainstream healthcare providers as dependable avenues of relief for millions of patients worldwide, fueling growth in the market.
This market research report on psychedelic drugs provides comprehensive analysis and insights that are critical to navigate this swiftly growing industry. Understand key trends, such as the emergence of depression spray treatments, alongside critical insights on market segmentation, competitive landscapes, and regional market specifics. By arming yourself with this knowledge, your business can plot a confident path forward through this intricate and evolving market space.
As mental health issues continue to climb globally, the psychedelic drug market is poised for expansion. With detailed insights into primary players, market value calculations, and poignant trends, this report enables you to seize opportunities and anticipate challenges in the psychedelic drug market. Don't get left behind, equip yourself with vital knowledge and data that the leading companies in the sector leverage for sustained growth and success.
Psychedelic drug refers to a group of psychoactive drugs that alter perception, mood, and thought processes. All of the senses are affected by psychedelics, which change a person's thinking, perception of time, and emotions. These include chemicals such as Lysergic acid diethylamid (LSD) and plants such as peyote. These medications are used to treat a variety of brain conditions.
The main types of psychedelic drugs are lysergic acid diethylamid, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.
The global psychedelic drugs market grew from $4.2 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psychedelic drugs market is expected to grow to $8.31 billion in 2027 at a CAGR of 14.5%.
The psychedelic drugs market research report is one of a series of new reports that provides psychedelic drug market statistics, including psychedelic drug industry global market size, regional shares, competitors with a psychedelic drug market share, detailed psychedelic drug market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The introduction of "depression spray" is the key trend gaining popularity in the psychedelic drug market. Major companies operating in the psychedelic drug market are introducing nasal spray drugs for major depressive disorders to sustain their position in the market. For instance, in August 2021, Hikma Pharmaceuticals plc, a UK based pharmaceutical company, launched KLOXXADO. KLOXXADO is an 8 mg nasal spray containing naloxone HCl. This spray is used for the immediate care of patients, both adults and children, with known or suspected opioid overdoses, as shown by respiratory depression and/or central nervous system depression.
In April 2022, Numinus, a Canada-based company that manufactures psychedelic medicine with holistic, integrated psychotherapy, acquired Novamind for a deal amount of $20.77 million. With this acquisition, Numinus is expected to expand its psychotherapy clinics in the US and develop advanced psychedelic programs. Novamind is a US-based mental health company and manufacturer of psychedelic medicine.
North America was the largest region in the psychedelic drug market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the psychedelic drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drug market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in 2020, according to the National Alliance on Mental Illness (NAMI), a US-based mental health organization, 21% of adults in America were suffering from mental illness in 2020, which amounted to 52.9 million people. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drug market.
The psychedelic drug market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Major players in the psychedelic drug market are Johnson & Johnson, Pfizer, Hikma Pharmaceuticals PLC, Roche Holding AG, Merck & Co Inc., Jazz Pharmaceuticals plc, COMPASS Pathways PLC, Celon Pharma S.A., Numinus Wellness Inc., AbbVie, Mylan N.V., Avadel, NeuroRx Inc., Klarisana, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Allergan Inc., Mota Ventures Corp., Seelos Therapeutics, Emmes Company, and Novatris International AG.
This product will be delivered within 1-3 business days.
The main types of psychedelic drugs are lysergic acid diethylamid, ketamine, phencyclidine, gamma-hydroxybutyric acid (GHB), and salvia. Lysergic Acid Diethylamide (LSD) is also known colloquially as acid. LSD is manufactured in crystalline form and then mixed with other inert ingredients or diluted as a liquid to produce an ingestible form. The various disease indications include depression and PTSD, which could be natural or synthetic. The numerous applications include treatment-resistant depression, opiate addiction, post-traumatic stress disorder, narcolepsy, and panic disorders, and are distributed through various channels such as hospital pharmacies, retail pharmacies, and online pharmacies.
The global psychedelic drugs market grew from $4.2 billion in 2022 to $4.83 billion in 2023 at a compound annual growth rate (CAGR) of 14.9%. The Russia-Ukraine war disrupted the chances of global economic recovery from the COVID-19 pandemic, at least in the short term. The war between these two countries has led to economic sanctions on multiple countries, a surge in commodity prices, and supply chain disruptions, causing inflation across goods and services and affecting many markets across the globe. The psychedelic drugs market is expected to grow to $8.31 billion in 2027 at a CAGR of 14.5%.
The psychedelic drugs market research report is one of a series of new reports that provides psychedelic drug market statistics, including psychedelic drug industry global market size, regional shares, competitors with a psychedelic drug market share, detailed psychedelic drug market segments, market trends and opportunities, and any further data you may need to thrive in the psychedelic drugs industry. This psychedelic drug market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.
The introduction of "depression spray" is the key trend gaining popularity in the psychedelic drug market. Major companies operating in the psychedelic drug market are introducing nasal spray drugs for major depressive disorders to sustain their position in the market. For instance, in August 2021, Hikma Pharmaceuticals plc, a UK based pharmaceutical company, launched KLOXXADO. KLOXXADO is an 8 mg nasal spray containing naloxone HCl. This spray is used for the immediate care of patients, both adults and children, with known or suspected opioid overdoses, as shown by respiratory depression and/or central nervous system depression.
In April 2022, Numinus, a Canada-based company that manufactures psychedelic medicine with holistic, integrated psychotherapy, acquired Novamind for a deal amount of $20.77 million. With this acquisition, Numinus is expected to expand its psychotherapy clinics in the US and develop advanced psychedelic programs. Novamind is a US-based mental health company and manufacturer of psychedelic medicine.
North America was the largest region in the psychedelic drug market in 2022. Asia-Pacific is expected to be the fastest-growing region in the forecast period. The regions covered in the psychedelic drug market report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.
The countries covered in the psychedelic drug market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA.
The increase in the cases of mental illnesses is expected to propel the growth of the psychedelic drug market going forward. Mental illnesses refer to health conditions involving changes in emotion, thinking, or behavior. Mental illnesses include conditions such as distress and post-traumatic stress disorder. Psychedelic drugs are used to treat depression and post-traumatic stress disorder, and their regular usage decreases mental illnesses. For instance, in 2020, according to the National Alliance on Mental Illness (NAMI), a US-based mental health organization, 21% of adults in America were suffering from mental illness in 2020, which amounted to 52.9 million people. Therefore, an increase in the number of cases of mental illnesses is driving the growth of the psychedelic drug market.
The psychedelic drug market consists of sales of psilocybin, PCP, cannabis, and ecstasy. Values in this market are ‘factory gate’ values, that is the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.
The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).
The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.
Major players in the psychedelic drug market are Johnson & Johnson, Pfizer, Hikma Pharmaceuticals PLC, Roche Holding AG, Merck & Co Inc., Jazz Pharmaceuticals plc, COMPASS Pathways PLC, Celon Pharma S.A., Numinus Wellness Inc., AbbVie, Mylan N.V., Avadel, NeuroRx Inc., Klarisana, AstraZeneca, Dr. Reddy’s Laboratories Ltd., Takeda Pharmaceutical Company Limited, Allergan Inc., Mota Ventures Corp., Seelos Therapeutics, Emmes Company, and Novatris International AG.
This product will be delivered within 1-3 business days.
Frequently Asked Questions about the Global Psychedelic Drugs Market
What is the estimated value of the Global Psychedelic Drugs Market?
What is the growth rate of the Global Psychedelic Drugs Market?
What is the forecasted size of the Global Psychedelic Drugs Market?
Who are the key companies in the Global Psychedelic Drugs Market?
| Report Attribute | Details |
|---|---|
| No. of Pages | 200 |
| Published | March 2023 |
| Forecast Period | 2023 - 2027 |
| Estimated Market Value ( USD | $ 4.83 billion |
| Forecasted Market Value ( USD | $ 8.31 billion |
| Compound Annual Growth Rate | 14.5% |
| Regions Covered | Global |
Table of Contents
1. Executive Summary2. Psychedelic Drugs Market Characteristics
3. Psychedelic Drugs Market Trends And Strategies
4. Psychedelic Drugs Market - Macro Economic Scenario
4.1 COVID-19 Impact On Psychedelic Drugs Market
4.2 Ukraine-Russia War Impact On Psychedelic Drugs Market
4.3 Impact Of High Inflation On Psychedelic Drugs Market
5. Psychedelic Drugs Market Size And Growth
5.1. Global Psychedelic Drugs Historic Market, 2017-2022, $ Billion
5.1.1. Drivers Of The Market
5.1.2. Restraints On The Market
5.2. Global Psychedelic Drugs Forecast Market, 2022-2027F, 2032F, $ Billion
5.2.1. Drivers Of The Market
5.2.2. Restraints On the Market
6. Psychedelic Drugs Market Segmentation
6.1. Global Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
- Lysergic Acid Diethylamid (LSD)
- Ketamine
- Phencyclidine
- Gamma Hydroxybutyric Acid (GHB)
- Salvia
- Depression
- PTSD
- Natural
- Synthetic
- Treatment Resistant depression
- Opiate addiction
- Post- Traumatic stress disorder
- Narcolepsy
- Panic Disorders
- Hospitals Pharmacy
- Retail Pharmacy
- Online Pharmacy
7.1. Global Psychedelic Drugs Market, Split By Region, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
7.2. Global Psychedelic Drugs Market, Split By Country, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
8. Asia-Pacific Psychedelic Drugs Market
8.1. Asia-Pacific Psychedelic Drugs Market Overview
- Region Information, Impact Of COVID-19, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
8.3. Asia-Pacific Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
9. China Psychedelic Drugs Market
9.1. China Psychedelic Drugs Market Overview
9.2. China Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F,$ Billion
9.3. China Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F,$ Billion
10. India Psychedelic Drugs Market
10.1. India Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
10.2. India Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
11. Japan Psychedelic Drugs Market
11.1. Japan Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
11.2. Japan Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
12. Australia Psychedelic Drugs Market
12.1. Australia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
12.2. Australia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
13. Indonesia Psychedelic Drugs Market
13.1. Indonesia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
13.2. Indonesia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
14. South Korea Psychedelic Drugs Market
14.1. South Korea Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
14.2. South Korea Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
15. Western Europe Psychedelic Drugs Market
15.1. Western Europe Psychedelic Drugs Market Overview
15.2. Western Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
15.3. Western Europe Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
16. UK Psychedelic Drugs Market
16.1. UK Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
16.2. UK Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
17. Germany Psychedelic Drugs Market
17.1. Germany Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
17.2. Germany Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
18. France Psychedelic Drugs Market
18.1. France Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
18.2. France Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
19. Eastern Europe Psychedelic Drugs Market
19.1. Eastern Europe Psychedelic Drugs Market Overview
19.2. Eastern Europe Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
19.3. Eastern Europe Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
20. Russia Psychedelic Drugs Market
20.1. Russia Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
20.2. Russia Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
21. North America Psychedelic Drugs Market
21.1. North America Psychedelic Drugs Market Overview
21.2. North America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
21.3. North America Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
22. USA Psychedelic Drugs Market
22.1. USA Psychedelic Drugs Market Overview
22.2. USA Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
22.3. USA Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
23. South America Psychedelic Drugs Market
23.1. South America Psychedelic Drugs Market Overview
23.2. South America Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
23.3. South America Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
24. Brazil Psychedelic Drugs Market
24.1. Brazil Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
24.2. Brazil Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
25. Middle East Psychedelic Drugs Market
25.1. Middle East Psychedelic Drugs Market Overview
25.2. Middle East Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
25.3. Middle East Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
26. Africa Psychedelic Drugs Market
26.1. Africa Psychedelic Drugs Market Overview
26.2. Africa Psychedelic Drugs Market, Segmentation By Type, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
26.3. Africa Psychedelic Drugs Market, Segmentation By Application, Historic and Forecast, 2017-2022, 2027F, 2032F, $ Billion
27. Psychedelic Drugs Market Competitive Landscape And Company Profiles
27.1. Psychedelic Drugs Market Competitive Landscape
27.2. Psychedelic Drugs Market Company Profiles
27.2.1. Johnson & Johnson
27.2.1.1. Overview
27.2.1.2. Products and Services
27.2.1.3. Strategy
27.2.1.4. Financial Performance
27.2.2. Pfizer
27.2.2.1. Overview
27.2.2.2. Products and Services
27.2.2.3. Strategy
27.2.2.4. Financial Performance
27.2.3. Hikma Pharmaceuticals PLC
27.2.3.1. Overview
27.2.3.2. Products and Services
27.2.3.3. Strategy
27.2.3.4. Financial Performance
27.2.4. Roche Holding AG
27.2.4.1. Overview
27.2.4.2. Products and Services
27.2.4.3. Strategy
27.2.4.4. Financial Performance
27.2.5. Merck & Co Inc
27.2.5.1. Overview
27.2.5.2. Products and Services
27.2.5.3. Strategy
27.2.5.4. Financial Performance
28. Key Mergers And Acquisitions In The Psychedelic Drugs Market
29. Psychedelic Drugs Market Future Outlook and Potential Analysis
30. Appendix
30.1. Abbreviations
30.2. Currencies
30.3. Historic And Forecast Inflation Rates
30.4. Research Inquiries
30.5. About the Publisher
30.6. Copyright And Disclaimer
Executive Summary
Psychedelic Drugs Global Market Report 2023 provides strategists, marketers and senior management with the critical information they need to assess the market.This report focuses on psychedelic drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.
Reasons to Purchase
- Gain a truly global perspective with the most comprehensive report available on this market covering 50+ geographies.
- Understand how the market has been affected by the COVID-19 and how it is responding as the impact of the virus abates.
- Assess the Russia - Ukraine war’s impact on agriculture, energy and mineral commodity supply and its direct and indirect impact on the market.
- Measure the impact of high global inflation on market growth.
- Create regional and country strategies on the basis of local data and analysis.
- Identify growth segments for investment.
- Outperform competitors using forecast data and the drivers and trends shaping the market.
- Understand customers based on the latest market shares.
- Benchmark performance against key competitors.
- Suitable for supporting your internal and external presentations with reliable high quality data and analysis
Description:
Where is the largest and fastest growing market for psychedelic drugs? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The psychedelic drugs market global report answers all these questions and many more.The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market’s historic and forecast market growth by geography.
Scope
Markets Covered:
1) By Type: Lysergic Acid Diethylamid (LSD); Ketamine; Phencyclidine; Gamma Hydroxybutyric Acid (GHB); Salvia2) By Disease Indication: Depression; PTSD
3) By Origin: Natural; Synthetic
4) By Application: Treatment-Resistant Depression; Opiate addiction; Post- Traumatic Stress Disorder; Narcolepsy; Panic Disorders
5) By Distribution Channel: Hospitals Pharmacy; Retail Pharmacy; Online Pharmacy
Companies Mentioned: Johnson & Johnson; Pfizer; Hikma Pharmaceuticals PLC; Roche Holding AG; Merck & Co Inc
Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA
Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
Time series: Five years historic and ten years forecast.
Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
Delivery Format: PDF, Word and Excel Data Dashboard.
Companies Mentioned
A selection of companies mentioned in this report includes:
- Johnson & Johnson
- Pfizer
- Hikma Pharmaceuticals PLC
- Roche Holding AG
- Merck & Co Inc
- Jazz Pharmaceuticals plc
- COMPASS Pathways PLC
- Celon Pharma S.A.
- Numinus Wellness Inc
- AbbVie
- Mylan N.V.
- Avadel
- NeuroRx Inc.
- Klarisana
- AstraZeneca
- Dr. Reddy’s Laboratories Ltd
- Takeda Pharmaceutical Company Limited
- Allergan Inc
- Mota Ventures Corp.
- Seelos Therapeutics
- Emmes Company
- Novatris International AG
Methodology
LOADING...
